FOCUS on PROTACs. On May 1st the first PROTAC, a heterobifunctional protein degrader and a new therapeutic modality, was approved by the FDA. Vepdegestrant (Arvinas’ Veppanu) has been approved as a treatment for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. “This milestone demonstrates that targeted protein degradation can translate into meaningful clinical impact.”
FOCUS Biomolecules can supply Vepdegestrant (ARV-471) for research applications. Contact us for more information.
